RAPP
NASDAQRapport Therapeutics Inc.
Price$42.53+2.09 (+5.18%)
01:30 PM07:45 PM
News · 26 weeks63-45%
2026-01-182026-07-12
Mix3490d
- Insider16(47%)
- SEC Filings12(35%)
- Other4(12%)
- Analyst2(6%)
Latest news
25 items- INSIDERChief Executive Officer Ceesay Abraham sold $328,437 worth of shares (8,210 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 539,817 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERChief Operating Officer Gault Cheryl sold $415,798 worth of shares (10,000 units at $41.58) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 149,914 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERChief Executive Officer Ceesay Abraham sold $327,398 worth of shares (8,220 units at $39.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 548,027 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- ANALYSTLeerink Partners initiated coverage on Rapport Therapeutics with a new price targetLeerink Partners initiated coverage of Rapport Therapeutics with a rating of Outperform and set a new price target of $52.00
- INSIDERSEC Form 4 filed by Director Maraganore John4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Perez Robert J4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Paul Steven M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Silva Paul M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Healy James4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Huber Reid M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Young Wendy B.4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Sanchez Ramiro4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- INSIDERLarge owner Third Rock Ventures V, L.P. sold $743,753 worth of shares (18,572 units at $40.05) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- PRRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceBOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET. Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL) – fireside chat on Monday, June 8, 2026, at 1:20 pm ET. Interested parties may access the live and archived webcasts of
- ANALYSTTruist resumed coverage on Rapport Therapeutics with a new price targetTruist resumed coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $56.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERLarge owner Third Rock Ventures V, L.P. sold $5,377,323 worth of shares (133,618 units at $40.24) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERLarge owner Third Rock Ventures V, L.P. sold $11,094,906 worth of shares (276,513 units at $40.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
RAPP FAQ
6 questionsWhere does RAPP stock trade?
Rapport Therapeutics Inc. (RAPP) is listed on NASDAQ.What sector and industry is RAPP in?
Rapport Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rapport Therapeutics Inc. go public?
Rapport Therapeutics Inc. (RAPP) completed its IPO in 2024.What are analysts saying about RAPP?
Rapport Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-06-24. Recent price targets range from $3100.00 to $4700.00.What companies are similar to RAPP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RAPP side-by-side with any of them on Quantisnow.How can I track RAPP on Quantisnow?
Quantisnow aggregates Rapport Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RAPP to receive live email and push alerts on every new disclosure.